News
ASCO 2025 First PARP Inhibitor Combo to Show Benefit in mCSPC Johnson & Johnson's AKEEGA® (niraparib + abiraterone acetate) is the first PARP-based combination to demonstrate statistically significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback